Pier 88 Investment Partners LLC Buys 220 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Pier 88 Investment Partners LLC grew its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 6.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,750 shares of the company’s stock after buying an additional 220 shares during the period. Pier 88 Investment Partners LLC’s holdings in Krystal Biotech were worth $587,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of KRYS. US Bancorp DE increased its stake in Krystal Biotech by 8.7% in the 4th quarter. US Bancorp DE now owns 1,027 shares of the company’s stock worth $161,000 after acquiring an additional 82 shares during the last quarter. Crossmark Global Holdings Inc. increased its position in shares of Krystal Biotech by 5.5% in the fourth quarter. Crossmark Global Holdings Inc. now owns 2,307 shares of the company’s stock worth $362,000 after purchasing an additional 121 shares during the last quarter. Perigon Wealth Management LLC raised its stake in Krystal Biotech by 1.5% in the fourth quarter. Perigon Wealth Management LLC now owns 8,289 shares of the company’s stock valued at $1,200,000 after purchasing an additional 123 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Krystal Biotech by 3.4% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,614 shares of the company’s stock valued at $840,000 after purchasing an additional 153 shares during the last quarter. Finally, Xponance Inc. grew its stake in Krystal Biotech by 9.5% in the 4th quarter. Xponance Inc. now owns 1,785 shares of the company’s stock worth $280,000 after buying an additional 155 shares in the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.

Krystal Biotech Stock Performance

Shares of KRYS stock opened at $183.92 on Monday. The company has a market capitalization of $5.30 billion, a P/E ratio of 61.51 and a beta of 0.87. Krystal Biotech, Inc. has a fifty-two week low of $141.72 and a fifty-two week high of $219.34. The stock has a 50 day moving average price of $170.82 and a two-hundred day moving average price of $173.55.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, beating analysts’ consensus estimates of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The company had revenue of $91.10 million during the quarter, compared to analyst estimates of $91.35 million. During the same period in the prior year, the business posted $0.30 EPS. The firm’s revenue was up 116.4% compared to the same quarter last year. As a group, equities analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Insider Transactions at Krystal Biotech

In related news, CAO Kathryn Romano sold 750 shares of the firm’s stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the sale, the chief accounting officer now owns 12,604 shares of the company’s stock, valued at $2,208,472.88. This trade represents a 5.62 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the sale, the insider now directly owns 1,463,711 shares of the company’s stock, valued at $260,233,178.69. The trade was a 1.68 % decrease in their position. The disclosure for this sale can be found here. 14.10% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Chardan Capital raised their price objective on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a research report on Thursday, February 20th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price target on shares of Krystal Biotech in a research note on Thursday, February 20th. HC Wainwright reiterated a “buy” rating and set a $221.00 price objective on shares of Krystal Biotech in a research report on Friday, February 28th. Citigroup boosted their target price on Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research report on Thursday, February 20th. Finally, Jefferies Financial Group initiated coverage on shares of Krystal Biotech in a research note on Wednesday, March 5th. They set a “buy” rating and a $245.00 price target on the stock. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $220.00.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).